Novel combination of insulin degludec and liraglutide (IDegLira) is efficacious across the range of disease progression in type 2 diabetes

被引：0
|
作者：
Rodbard, H. W. [1 ]
Buse, J. B. [2 ]
Woo, V. C. [3 ]
Vilsboll, T. [4 ]
Langbakke, I. [5 ]
Korsholm, L. [5 ]
Gough, S. [6 ]
机构：
[1] Endocrine & Metab Consultants, Rockville, MD USA
[2] Univ N Carolina, Sch Med, Chapel Hill, NC USA
[3] Univ Manitoba, Winnipeg, MB, Canada
[4] Univ Copenhagen, Hellerup, Denmark
[5] Novo Nordisk AS, Soborg, Denmark
[6] Univ Oxford, Oxford OX1 2JD, England
来源：
DIABETOLOGIA | 2014年 / 57卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
835
引用
收藏
页码：S338 / S339
页数：2
相关论文
共 50 条
  • [41] Insulin Degludec/Liraglutide (IDegLira) Is Efficacious and Safe in Patients with Type 2 Diabetes (T2D) with Normal, Mild, or Moderate Renal Impairment: Analyses from Phase 3 Trials
    Aroda, Vanita R.
    Bode, Bruce W.
    Davidson, Jaime
    Rodbard, Helena W.
    Andersen, Andreas
    Kaas, Anne
    Vilsboll, Tina
    DIABETES, 2017, 66 : A286 - A286
  • [42] Patients with type 2 diabetes on the maximum dose of insulin degludec/liraglutide (IDegLira) achieve glycaemic target: analyses from the DUAL programme
    Meneghini, L.
    Linjawi, S.
    Serusclat, P.
    Vilsboll, T.
    Agner, B. F.
    Hansen, T.
    Leiter, L. A.
    DIABETOLOGIA, 2018, 61 : S413 - S413
  • [43] A Fixed Ratio Combination of Insulin Degludec and Liraglutide (IDegLira) Reduces Glycemic Fluctuation and Brings More Patients with Type 2 Diabetes Within Blood Glucose Target Ranges
    King, Allen B.
    Philis-Tsimikas, Athena
    Kilpatrick, Eric S.
    Langbakke, Irene H.
    Begtrup, Kamilla
    Vilsboll, Tina
    DIABETES TECHNOLOGY & THERAPEUTICS, 2017, 19 (04) : 255 - 264
  • [44] Insulin degludec/liraglutide (IDegLira) improves patient-reported outcomes in subjects with type 2 diabetes uncontrolled on insulin glargine plus metformin: DUALV
    Lingvay, I.
    Manghi, F. C. Perez
    Garcia-Hernandez, P. A.
    Norwood, P.
    Jarlov, H.
    Kongso, J. H.
    Brod, M.
    DIABETOLOGIA, 2015, 58 : S400 - S400
  • [45] Efficacy and safety of insulin degludec/liraglutide (IDegLira) vs basal-bolus therapy in patients with type 2 diabetes: DUAL VII trial
    Billings, L. K.
    Doshi, A.
    Gouet, D.
    Oviedo, A.
    Rodbard, H. W.
    Tentolouris, N.
    Gron, R.
    Halladin, N.
    Jodar, E.
    DIABETOLOGIA, 2017, 60 : S366 - S366
  • [46] Benefits of combination of insulin degludec and liraglutide are independent of baseline glycated haemoglobin level and duration of type 2 diabetes
    Rodbard, H. W.
    Buse, J. B.
    Woo, V.
    Vilsboll, T.
    Langbakke, I. H.
    Kvist, K.
    Gough, S. C. L.
    DIABETES OBESITY & METABOLISM, 2016, 18 (01): : 40 - 48
  • [47] Can a fixed-ratio combination of insulin degludec and liraglutide help Type 2 diabetes patients to optimize glycemic control across the day?
    Simpson, Richard
    King, Allen
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2015, 8 (02) : 179 - 188
  • [48] Type 2 Diabetes Patients Reach Target Glycemic Control Faster Using IDegLira than Either Insulin Degludec or Liraglutide Given Alone
    Vilsboll, Tina
    Vora, Jiten
    Jarlov, Henrik
    Kvist, Kajsa
    Blonde, Lawrence
    CLINICAL DRUG INVESTIGATION, 2016, 36 (04) : 293 - 303
  • [49] Type 2 Diabetes Patients Reach Target Glycemic Control Faster Using IDegLira than Either Insulin Degludec or Liraglutide Given Alone
    Tina Vilsbøll
    Jiten Vora
    Henrik Jarlov
    Kajsa Kvist
    Lawrence Blonde
    Clinical Drug Investigation, 2016, 36 : 293 - 303
  • [50] Preserved pharmacokinetic properties and distinct glycaemic effects of insulin degludec and liraglutide in IDegLira, a fixed ratio combination product
    Kapitza, C.
    Bode, B. W.
    Ingwersen, S. H.
    Jacobsen, L. V.
    Poulsen, P.
    DIABETOLOGIA, 2014, 57 : S392 - S393
12345